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The clinically approved proteasome inhibitor bortezomib
(Bz) represents a promising agent for the therapy of
relapsed multiple myeloma. However, long-term remis-
sions are difficult to achieve, in fact myeloma cells often
develop secondary resistance to proteasome inhibition.
We recently demonstrated that myeloma cells are highly
sensitive towards proteasome inhibitors due to their
extensive rate of immunoglobulin synthesis, thereby trig-
gering the terminal unfolded protein response (UPR) and
apoptosis via endoplasmic reticulum (ER) stress. We want
to identify synergistic agents sensitizing myeloma cells
towards Bz. The calcium channel blocker verapamil has
been shown to inhibit proliferation of leukemia cells and
to interfere with multi drug resistance-based drug elimina-
tion. Hence, we analysed the effect of Bz together with ver-
apamil on the viability and ER-stress in different human
myeloma cell lines. The combination of Bz and verapamil
synergistically decreased cell viability of myeloma cell
lines by inducing apoptotic and necrotic cell death.
Importantly, Bz-mediated activation of major UPR signal-
ling pathways was enhanced by verapamil. The Bz/vera-
pamil treatment also resulted in caspase activation
followed by PARP cleavage. NF-kB DNA-binding activity
markedly declined in myeloma cells treated with both
agents. In contrast to Bz, proteasomal activity was not
altered by verapamil. However, the amount of ubiquiti-
nylated proteins in detergent-insoluble fractions was
much higher in the presence of Bz/verapamil compared to
Bz alone, suggesting increased formation of protein aggre-
gates within the cell. Beside that, verapamil reduced
expression of the multi drug resistance protein 1 and
impaired drug-efflux in the myeloma cells. We conclude
that verapamil increased the pro-apoptotic effect of Bz by
inducing additional ER-stress signals along with inhibit-
ing the NF-kB activity and modulating drug transport
mechanism. Thus, the combination therapy Bz/verapamil
may provide a more effective treatment-strategy for multi-
ple myeloma than the Bz-monotherapy and overcome
drug resistance.
from 12th Joint Meeting of the Signal Transduction Society (STS). Signal Transduction: Receptors, Mediators and Genes
Weimar, Germany. 29–31 October 2008
Published: 26 February 2009
Cell Communication and Signaling 2009, 7(Suppl 1):A34 doi:10.1186/1478-811X-7-S1-A34
<supplement> <title> <p>12th Joint Meeting of the Signal Transduction Society (STS). Signal Transduction: Receptors, Mediators and Genes</p> </title> <editor>Frank Entschladen, Karlheinz Friedrich, Ralf Hass and Ottmar Janssen</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1478-811X-7-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.biosignaling.com/content/7/S1/A34
© 2009 Meister et al; licensee BioMed Central Ltd. 
